Event | 34th Annual Roth Conference |
Date | March 15, 2022 |
Time | 2:30 PM Pacific Time (5:30 PM Eastern Time) |
Format | Fireside Chat |
Link | https://wsw.com/webcast/roth43/nvct/1845484 |
About Nuvectis Pharma
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. The Company's pipeline includes NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor in IND-enabling pre-clinical testing.
For more information, please visit www.nuvectis.com.
Nuvectis Pharma Contact:
Ron Bentsur
Chairman, Chief Executive Officer and President
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Relations Contact:
LifeSci Advisors on behalf of Nuvectis Pharma, Inc.
Eric Goldstein
Tel: 646-791-9729
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$6.65 |
Daily Change: | -0.12 -1.77 |
Daily Volume: | 124,752 |
Market Cap: | US$122.160M |
March 19, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB